Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant788 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02410577 | 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme | completed | N/A | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01810744 | Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma(BEVACAPI) | completed | N/A | 47 | Centre Georges Francois LeclercOTHER | 1 | Mar 15, 2019 |
| clinicaltrials |
| NCT02768389 | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | completed | Early Phase 1 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02189109 | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma(GBM) | completed | Phase 1 | 11 | NuvOx LLCINDUSTRY | 1 | Feb 28, 2019 | clinicaltrials |
| NCT02575027 | Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme | completed | N/A | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT02632370 | 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor | completed | — | 69 | Constantinos HadjipanayisOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT00977431 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | completed | Phase 1 | 36 | Boehringer IngelheimINDUSTRY | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01873469 | Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme | completed | — | 102 | Technische Universität DresdenOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT03291314 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma(GliAvAx) | completed | Phase 2 | 52 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | completed | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT02853565 | A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 10 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01653834 | Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas | completed | N/A | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT02454634 | Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas(NOA-16) | completed | Phase 1 | 39 | National Center for Tumor Diseases, HeidelbergOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT02300506 | Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma | completed | — | 507 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 5, 2018 | clinicaltrials |
| NCT02023346 | Prognostic Awareness and Patient-Physician Communication in Malignant Glioma | completed | — | 95 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT02728349 | Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma | completed | Phase 1 | 26 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00038441 | Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas | completed | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02966509 | Engagement of Patients With Advanced Cancer(EPAC) | completed | N/A | 213 | Stanford UniversityOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT00038493 | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02511405 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)(GLOBE) | completed | Phase 3 | 252 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 3 | Oct 23, 2018 | clinicaltrials |
| NCT02718443 | VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | completed | Phase 1 | 14 | Vaximm GmbHINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00323115 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01967758 | Phase I Study of Safety and Immunogenicity of ADU-623 | completed | Phase 1 | 11 | Providence Health & ServicesOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT02666066 | Radiomics for Prediction of Survival in GBM(Radiomics) | completed | — | 289 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | completed | Phase 2 | 58 | Massachusetts General HospitalOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT00782626 | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02049489 | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | completed | Phase 1 | 20 | Precision Life Sciences GroupINDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02149225 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | completed | Phase 1 | 16 | Immatics Biotechnologies GmbHINDUSTRY | 5 | Aug 7, 2018 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT01151670 | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02698280 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | completed | Phase 2 | 23 | Huashan HospitalOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02478164 | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01907165 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00919750 | Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors | completed | — | 1,258 | Children's Oncology GroupNETWORK | 6 | Jul 16, 2018 | clinicaltrials |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | completed | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01644955 | Carboplatin in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 10 | James ElderOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02041611 | Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas | completed | N/A | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT01450826 | Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | completed | Phase 2 | 136 | Katy PetersOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT02186262 | Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas(RODIG) | completed | — | 36 | Turku University HospitalOTHER_GOV | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01091792 | Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) | completed | Early Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 25, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Mar 19, 2019source: clinicaltrials